810 related articles for article (PubMed ID: 33691171)
1. A pan-cancer analysis of the HER family gene and their association with prognosis, tumor microenvironment, and therapeutic targets.
Yang X; Miao Y; Wang J; Mi D
Life Sci; 2021 May; 273():119307. PubMed ID: 33691171
[TBL] [Abstract][Full Text] [Related]
2. Pan-Cancer Analysis of the TRP Family, Especially TRPV4 and TRPC4, and Its Expression Correlated with Prognosis, Tumor Microenvironment, and Treatment Sensitivity.
Chen Z; Zhao Y; Tian Y; Cao R; Shang D
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830651
[TBL] [Abstract][Full Text] [Related]
3. Pan-cancer analysis of SERPINE family genes as biomarkers of cancer prognosis and response to therapy.
Liu Y; Li X; Chen S; Zhu C; Shi Y; Dang S; Zhang W; Li W
Front Mol Biosci; 2023; 10():1277508. PubMed ID: 38274096
[No Abstract] [Full Text] [Related]
4. A pan-cancer study of class-3 semaphorins as therapeutic targets in cancer.
Zhang X; Klamer B; Li J; Fernandez S; Li L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):45. PubMed ID: 32241267
[TBL] [Abstract][Full Text] [Related]
5. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
6. A Pan-Cancer Analysis of the BIRC Gene Family and Its Association with Prognosis, Tumor Microenvironment, and Therapeutic Targets.
Wu S; Zang Q; Xing Z; Li X; Leng J; Liu Y; Wang X; Yang J
Crit Rev Eukaryot Gene Expr; 2021; 31(4):35-48. PubMed ID: 34587434
[TBL] [Abstract][Full Text] [Related]
7. Investigation of lipid metabolism dysregulation and the effects on immune microenvironments in pan-cancer using multiple omics data.
Hao Y; Li D; Xu Y; Ouyang J; Wang Y; Zhang Y; Li B; Xie L; Qin G
BMC Bioinformatics; 2019 May; 20(Suppl 7):195. PubMed ID: 31074374
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive pan-cancer analysis of YBX family reveals YBX2 as a potential biomarker in liver cancer.
Yuan Z; Li B; Liao W; Kang D; Deng X; Tang H; Xie J; Hu D; Chen A
Front Immunol; 2024; 15():1382520. PubMed ID: 38698857
[TBL] [Abstract][Full Text] [Related]
9. Broadening Drug Design and Targets to Tumor Microenvironment? Cancer-Associated Fibroblast Marker Expression in Cancers and Relevance for Survival Outcomes.
Dzobo K; Dandara C
OMICS; 2020 Jun; 24(6):340-351. PubMed ID: 32496971
[TBL] [Abstract][Full Text] [Related]
10. A pan-cancer analysis of collagen VI family on prognosis, tumor microenvironment, and its potential therapeutic effect.
Li X; Li Z; Gu S; Zhao X
BMC Bioinformatics; 2022 Sep; 23(1):390. PubMed ID: 36167487
[TBL] [Abstract][Full Text] [Related]
11. TMX family genes and their association with prognosis, immune infiltration, and chemotherapy in human pan-cancer.
Luo N; Mei Z; Zhang Q; Tang H; Wan R; Deng A; Zou X; Lv C
Aging (Albany NY); 2023 Dec; 15(24):15064-15083. PubMed ID: 38147024
[TBL] [Abstract][Full Text] [Related]
12. The panoramic picture of pepsinogen gene family with pan-cancer.
Shen S; Li H; Liu J; Sun L; Yuan Y
Cancer Med; 2020 Dec; 9(23):9064-9080. PubMed ID: 33067881
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value and immunological role of PDCD1 gene in pan-cancer.
Miao Y; Wang J; Li Q; Quan W; Wang Y; Li C; Wu J; Mi D
Int Immunopharmacol; 2020 Dec; 89(Pt B):107080. PubMed ID: 33069926
[TBL] [Abstract][Full Text] [Related]
14. Bioinformatics and survival analysis of glia maturation factor-γ in pan-cancers.
Lan A; Ren C; Wang X; Tong G; Yang G
BMC Cancer; 2021 Apr; 21(1):423. PubMed ID: 33863293
[TBL] [Abstract][Full Text] [Related]
15. VDR is a potential prognostic biomarker and positively correlated with immune infiltration: a comprehensive pan-cancer analysis with experimental verification.
Xia X; Xu F; Dai D; Xiong A; Sun R; Ling Y; Qiu L; Wang R; Ding Y; Lin M; Li H; Xie Z
Biosci Rep; 2024 May; 44(5):. PubMed ID: 38639057
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the role of Frizzled 2 in different cancer types.
Zhou M; Sun X; Zhu Y
FEBS Open Bio; 2021 Apr; 11(4):1195-1208. PubMed ID: 33565732
[TBL] [Abstract][Full Text] [Related]
17. The Diagnostic and Prognostic Value of LIMK1/2: A Pan-Cancer Analysis.
Li J; Liu Y; Zheng L
Ann Clin Lab Sci; 2021 Sep; 51(5):615-624. PubMed ID: 34686503
[TBL] [Abstract][Full Text] [Related]
18. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H
Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579
[TBL] [Abstract][Full Text] [Related]
19. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
20. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
